中文摘要
多发性骨髓瘤(MM)是一种克隆性血液系统恶性肿瘤,其特征是完全缓解率低。细胞因子诱导的杀伤(CIK)细胞疗法在MM治疗中显示出有前景的获益。
在本研究中,我们探讨了巨噬细胞分泌的促炎细胞因子是否能上调MICA/B表达,从而增强CIK细胞的细胞毒性。采用流式细胞术进行CIK细胞的表型检测和细胞毒性实验。使用ELISA法检测可溶性MICA/B和巨噬细胞来源的细胞因子。采用CCK-8实验评估细胞活力。使用RT-qPCR研究基因表达水平。促炎细胞因子上调了MM细胞中MICA/B和PD-L1的表达。促炎细胞因子增强了CIK细胞对MM细胞的细胞毒性,其中TNF-α表现出比IL-1β和IL-6更强的作用,因为它同时增强了NKG2D-MICA/B轴的两个组成部分。PD-L1阻断促进了CIK细胞的细胞毒性能力。在机制上,IL-1β、IL-6和TNF-α通过PI3K/AKT、JAK/STAT3和MKK/p38 MAPK通路增强了MICA/B和PD-L1基因的转录。促炎细胞因子上调了MICA/B和PD-L1的表达,从而通过增强NKG2D通路促进CIK细胞对MM的细胞毒性,而PD-L1阻断则增强了CIK细胞的细胞毒性。
展开英文摘要原文
Multiple myeloma (MM) is a clonal hematologic malignancy characterized by low rate of complete remissions. Cytokine-induced killer (CIK) cell therapy has shown promising benefits in MM treatment. In this study, we investigated whether the pro-inflammatory cytokines secreted by macrophages could upregulate MICA/B expression and thus the cytotoxicity of CIK cells. Flow cytometry was used for phenotypic measurement and the cytotoxicity assay of CIK cells. Soluble MICA/B and macrophage-derived cytokines were measured using ELISA assay.
CCK-8 assay was applied to evaluate cell viabilities. Gene expression levels were investigated using RT-qPCR. The expression of MICA/B and PD-L1 in MM cells was upregulated by pro-inflammatory cytokines. Pro-inflammatory cytokines enhanced the cytotoxicity of CIK cells against MM cells, with TNF-α exhibiting a more potent effect than IL-1β and IL-6 as it strengthened both components of the NKG2D-MICA/B axis. PD-L1 blockade promoted the cytotoxic ability of CIK cells.
Mechanistically, IL-1β, IL-6, and TNF-α enhanced the transcription of MICA/B and PD-L1 genes via the PI3K/AKT, JAK/STAT3, and MKK/p38 MAPK pathways. Pro-inflammatory cytokines upregulated the expression of MICA/B and PD-L1, thereby promoting the cytotoxicity of CIK cells against MM by strengthening the NKG2D pathway, while PD-L1 blockade enhanced the cytotoxicity of CIK cells.
论文信息
- 作者
- Chen P、Chen Y、Wang Y、Sharma A、Veronika LK、Weiher H、Maria AG、Schmidt-Wolf IGH
- 第一作者单位
- Department of Integrated Oncology, Center for Integrated Oncology (CIO), University Hospital Bonn, 53127, Bonn, Germany.Germany
- 通讯作者单位
- Department of Integrated Oncology, Center for Integrated Oncology (CIO), University Hospital Bonn, 53127, Bonn, Germany. Ingo.Schmidt-Wolf@ukbonn.de.Germany
- 期刊
- Scientific reports2025 May 14